Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292318475> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4292318475 endingPage "157" @default.
- W4292318475 startingPage "151" @default.
- W4292318475 abstract "Objective: Despite of non-vitamin K antagonist oral anticoagulants (NOACs) is a preferred oral anticoagulant but in limited-resource country, warfarin still be first line drug. Bridging parenteral anticoagulant with warfarin is required in particular circumstances. Since a NOACs contains rapid onset and steady activity characteristics, then the use of NOACs instead of traditional parenteral anticoagulant to bridging with warfarin is intriguing. Materials and Methods: We conducted an open-label, randomized, pilot study in patients with atrial fibrillation (AF) and thromboembolism who considerably required bridging therapy to apixaban (5 mg orally bid) or enoxaparin (1 mg/kg subcutaneously every 12 hours) bridging to warfarin. The dose of warfarin was adjusted every 3 to 5 days to achieve the goal of international normalized ratio (INR) between 2 to 3 before stopping the bridging. The primary outcome was bleeding complication classified as the Bleeding Academic Research Consortium (BARC) criteria. The secondary outcome included thromboembolic complication, mean change of hemoglobin (Hb) level during bridging, and cost of anticoagulant. Results: A total of 37 patients underwent randomization after stratified to AF and thromboembolism groups from 60 patients screened, which 19 assigned to apixaban and 18 to enoxaparin. Six patients were excluded after randomization (1 in apixaban group and 5 in enoxaparin group), the data before the patients were excluded were used in the analysis. The median (interquartile range) bridging duration was 7 (5 to 10) and 9 (6 to 14.5) days for apixaban and enoxaparin, respectively. There was null BARC bleeding in apixaban group whereas 3 patients developed BARC 1 bleeding in enoxaparin group (p=0.058). Thromboembolic complication was not occurred in any group during the bridging. The median cost of anticoagulant was 674 and 4,352 Thai Baht (p<0.001) and mean change of Hb level was +0.36 and -0.38 g/dl in apixaban and enoxaparin group (p=0.029), respectively. Conclusion: Apixaban was as safe, effective, and less expensive than enoxaparin in bridging to warfarin in patients with AF and thromboembolism. Keywords: Bridging anticoagulant; NOACs; Apixaban; Enoxaparin; Warfarin" @default.
- W4292318475 created "2022-08-19" @default.
- W4292318475 date "2021-10-15" @default.
- W4292318475 modified "2023-09-25" @default.
- W4292318475 title "Bridging to Warfarin with Apixaban versus Conventional Heparin: An Open Label, Pilot, Randomized Controlled Trial" @default.
- W4292318475 doi "https://doi.org/10.35755/jmedassocthai.2021.s04.00060" @default.
- W4292318475 hasPublicationYear "2021" @default.
- W4292318475 type Work @default.
- W4292318475 citedByCount "0" @default.
- W4292318475 crossrefType "journal-article" @default.
- W4292318475 hasConcept C126322002 @default.
- W4292318475 hasConcept C141071460 @default.
- W4292318475 hasConcept C168563851 @default.
- W4292318475 hasConcept C174348530 @default.
- W4292318475 hasConcept C2776301958 @default.
- W4292318475 hasConcept C2777557582 @default.
- W4292318475 hasConcept C2778661090 @default.
- W4292318475 hasConcept C2779161974 @default.
- W4292318475 hasConcept C2780638905 @default.
- W4292318475 hasConcept C3019800554 @default.
- W4292318475 hasConcept C31258907 @default.
- W4292318475 hasConcept C41008148 @default.
- W4292318475 hasConcept C71924100 @default.
- W4292318475 hasConceptScore W4292318475C126322002 @default.
- W4292318475 hasConceptScore W4292318475C141071460 @default.
- W4292318475 hasConceptScore W4292318475C168563851 @default.
- W4292318475 hasConceptScore W4292318475C174348530 @default.
- W4292318475 hasConceptScore W4292318475C2776301958 @default.
- W4292318475 hasConceptScore W4292318475C2777557582 @default.
- W4292318475 hasConceptScore W4292318475C2778661090 @default.
- W4292318475 hasConceptScore W4292318475C2779161974 @default.
- W4292318475 hasConceptScore W4292318475C2780638905 @default.
- W4292318475 hasConceptScore W4292318475C3019800554 @default.
- W4292318475 hasConceptScore W4292318475C31258907 @default.
- W4292318475 hasConceptScore W4292318475C41008148 @default.
- W4292318475 hasConceptScore W4292318475C71924100 @default.
- W4292318475 hasIssue "Suppl. 4" @default.
- W4292318475 hasLocation W42923184751 @default.
- W4292318475 hasOpenAccess W4292318475 @default.
- W4292318475 hasPrimaryLocation W42923184751 @default.
- W4292318475 hasRelatedWork W2176949176 @default.
- W4292318475 hasRelatedWork W2332994135 @default.
- W4292318475 hasRelatedWork W2579392307 @default.
- W4292318475 hasRelatedWork W2730955137 @default.
- W4292318475 hasRelatedWork W2765469496 @default.
- W4292318475 hasRelatedWork W2892248211 @default.
- W4292318475 hasRelatedWork W3110909176 @default.
- W4292318475 hasRelatedWork W4206203112 @default.
- W4292318475 hasRelatedWork W4241684568 @default.
- W4292318475 hasRelatedWork W4245228749 @default.
- W4292318475 hasVolume "104" @default.
- W4292318475 isParatext "false" @default.
- W4292318475 isRetracted "false" @default.
- W4292318475 workType "article" @default.